특집-갑상선암의 최신지견 : 갑상선암의 분자표적치료 = Special Review : Molecular targeted therapy of thyroid cancer

다국어 초록 (Multilingual Abstract)

Novel molecular-targeted therapies involving various kinds of kinase inhibitors show promising results in the treatment of advanced thyroid carcinoma refractory to conventional treatment such as surgery and radioiodine treatment. Partial response rates around 15~30% and disease stabilization in additional 30~60% are reported in clinical trials using these drugs. In this review, the introduction about many kinase inhibitors in clinical trials nowadays and the results focusing on phase 2 trial will be discussed. With the development of this various kinds of potent kinase inhibitors and encouragement of enrollment to further clinical trials will give hope to the patients with refractory thyroid cancer in the near future. (Korean J Med 77:559-564, 2009)

참고문헌 (Reference)

1 국립암센터, "대장-전립선-유방-갑상샘암 증가하고 암환자의 5년 생존율은 52.2%로 11.0% 향상 [보도자료]" 국립암센터 2008

2 Ain KB, "Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas" 17 : 663-670, 2007

3 Kloos RT, "Phase II trial of sorafenib in metastatic thyroid cancer" 27 : 1675-1684, 2009

4 Gupta-Abramson V, "Phase II trial of sorafenib in advanced thyroid cancer" 26 : 4714-4719, 2008

5 Cooney M, "Phase II study of combretastatin A4 phosphate (CA4P) in patients with advanced anaplastic thyroid carcinoma (ATC)" 5580-, 2006

6 Cohen E, "Phase 2 study of sunitinib in refractory thyroid cancer [Abstract]" 26 : 6025-, 2008

7 Woyach JA, "New therapeutic advances in the management of progressive thyroid cancer" 16 : 715-731, 2009

8 Sherman SI, "Motesanib diphosphate in progressive differentiated thyroid cancer" 359 : 31-42, 2008

9 Kilfoy BA, "International patterns and trends in thyroid cancer incidence, 1973-2002" 20 : 525-531, 2009

10 Davies L, "Increasing incidence of thyroid cancer in the United States, 1973-2002" 295 : 2164-2167, 2006

11 Shaha AR, "Differentiated thyroid cancer presenting initially with distant metastasis" 174 : 474-476, 1997

12 Ekman ET, "Chemotherapy and multimodality treatment in thyroid carcinoma" 23 : 523-527, 1990

13 National Cancer Center, Korea, "Cancer registry and statistics between 2003-2005" National Cancer Centre

14 Cohen EE, "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study" 26 : 4708-4713, 2008

15 Ferrara N, "Angiogenesis as a therapeutic target" 438 : 967-974, 2005

16 Sherman SI, "Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers" 94 : 1493-1499, 2009

17 de Groot JW, "A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma" 92 : 3466-3469, 2007

18 Pennell NA, "A phase II study of gefitinib in patients with advanced thyroid cancer" 18 : 317-323, 2008

19 Salgia R, "A phase I study of Xl184, a RET, VEGFR2 and MET kinase inhibitor, in patients with advanced malignancies, including pts with medullary thyroid carcinoma [Abstract]" 26 : 3522-, 2008

20 Hundahl SA, "A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995" 83 : 2638-2648, 1998